# Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

> **NCT03386721** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 256 (actual)

## Conditions studied

- Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers

## Interventions

- **DRUG:** simlukafusp alfa
- **DRUG:** Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT03386721
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-19
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 256 (ACTUAL)
- **Why stopped:** The Sponsor discontinued the development of Simlukafusp alfa due to portfolio prioritization, not due to any safety, efficacy, or quality issues.
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386721, "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03386721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*